Inspired by nature. Engineered for precision. Focused on patients.
At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages.
Immunotherapy thought differently
OUR PATH TO INNOVATION
1.
Metagenomics analysis across diverse geographical regions revealed a striking pattern: certain bacterial species were significantly underrepresented in cancer patients compared to healthy individuals.
2.
When these species were orally administered to mice with tumors, they triggered a potent anti-tumor response. Our research team discovered that a bacterial metabolite that derived from the applied species was responsible for this effect.
3.
Subsequent research uncovered that this metabolite acts as a modulator of a specific target receptor on tumor-associated macrophages. Once stimulated, the released cytokines activate the cytotoxic T-cells, leading to enhanced tumor infiltration and a potent anti-tumor effect.
4.
By developing a synthetic small molecule that replicates this mechanism, we are developing an effective and tolerable immunotherapy which is targeted at immune cells in the tumor. Our goal is to improve target activation, bioavailability, and stability, thereby maximizing efficacy to deliver groundbreaking therapeutic potential.
AI-Powered Drug Compound Discovery
Our cutting-edge generative AI models explore a vast chemical space to accelerate the discovery of novel compounds from hits to drug candidates. By combining physics-informed machine learning with generative AI, we predict and design optimized molecules with ideal properties. This approach enables a highly streamlined search for drug candidates with optimal affinity and selectivity— vastly accelerating our development of next-generation immunotherapeutics.
